Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Serum Fibrinogen in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis
Serum Factor VIII activity in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis
Serum Plasminogen activity in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis
Serum D-dimer in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis
Serum Fibrin degradation product in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis
Serum PAI-1 antigen in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis
Serum PAI-1 SNP genotyping in active PCV and CSC patients
Timeframe: Less than 1 week after initial diagnosis